CEO total compensation of approximately $23.3 million is elevated relative to a typical mid-cap biotech CEO benchmark, driven largely by a December 2025 grant of performance stock awards (units that vest only if PTC's stock outperforms the Nasdaq Biotechnology Index at the 55th percentile or higher over a three-year period) valued at roughly $12.4 million at target — these are genuine performance-contingent awards, not fixed pay disguised as variable pay. The pay mix is strongly performance-oriented: the company discloses that approximately 95.9% of the CEO's primary compensation is variable or at-risk, well above the policy's 50-60% threshold, and the 2025 cash incentive payout of 145% of target was supported by tangible results including regulatory approvals for Sephience in the U.S., EU, and Japan, product revenues exceeding guidance at $831 million, and 68% TSR in calendar year 2025 — outcomes that justify above-target incentive pay. The prior year say-on-pay vote received 96.8% support, there are no governance concerns with the clawback policy (a compliant Dodd-Frank clawback is in place), and variable incentive pay is well-aligned with shareholder outcomes.

Ernst & Young has audited PTC since 2010 (approximately 16 years), which is below the 25-year threshold that would raise tenure concerns; non-audit fees (primarily tax services) were $397,364 versus audit fees of $2,414,831, a ratio of about 16% — well below the 50% threshold that would raise independence concerns; EY is a Big 4 firm appropriate for a $6 billion market cap company.